PolyPid

PYPD

Market cap $65.7M

Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX₁₀₀ Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX₁₀₀

PolyPid Ltd. ( PYPD ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Dikla Akselbrad - CEO & Director Ori Warshavsky - Chief Operating Officer - US Jonny Missulawin - Chief Financial Officer Conference Call Participants Yehuda Leibler Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Brandon Folkes - H.C.

Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026

PETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company focused on improving surgical outcomes, today announced that D-PLEX₁₀₀, the company's lead candidate, has been named "Therapeutics Solution of the Year" by BioTech Breakthrough , a leading independent market intelligence organization which evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world's leading surgical conferences The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world's leading surgical conferences

PETACH TIKVA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that management will be presenting at the Lytham Partners Fall 2025 Virtual Investor Conference on September 30, 2025. Additionally, management will be participating in the upcoming 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025.

PETACH TIKVA, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd.

PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participate in the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-9, 2025, at the Lotte New York Palace Hotel, New York City.

PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dalit Hazan, Deputy CEO, EVP R&D, Clinical, and Regulatory Affairs, will present at the 14th meeting of the Israel Controlled Release Society (ICRS) Conference taking place at the Enjoy Hotel, Dead Sea, in Israel from September 7-9, 2025.